Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
R.A. Rizza, J.E. Gerich, M.W. Haymond, R.E. Westland, L.D. Hall, A.H. Clemens, et al.
Control of blood sugar in insulin-dependent diabetes: comparison of an artificial endocrine pancreas, continuous subcutaneous insulin infusion and intensified conventional therapy.
N Engl J Med, 303 (1980), pp. 1313-1318
[2.]
Diagnostic and therapeutic technology assessment (DATTA).
Continuous subcutaneous insulin infusion.
JAMA, 262 (1989), pp. 1239-1243
[3.]
P.J. Watkins.
Pros and cons of continuous subcutaneous insulin infusion.
BMJ, 290 (1985), pp. 655-656
[4.]
A. Schiffrin.
Nighttime continuous subcutaneous insulin infusion revisited: a strategy for improving insulin delivery.
Diabetes Care, 23 (2000), pp. 571-573
[5.]
C.D. Saudech.
Novel forms of insulin delivery.
Endocrinol Metab Clin North Am, 26 (1997), pp. 599-610
[6.]
C. Pagnoux, X. Nassif, C. Boitard, J. Timsit.
Infection of continuous subcutaneous insulin infusion site with Mycobacterium peregrinum.
Diabetes Care, 21 (1998), pp. 191-192
[7.]
N. Attia, T.W. Jones, J. Holcombe, W.V. Tamborlane.
Comparison of human regular and lispro insulins after interruption of continuous subcutaneous insulin infusion and in the treatment of acutely decompensated IDDM.
Diabetes Care, 21 (1998), pp. 817-821
[8.]
The Diabetes Control and Complications Trial Research Group.
The effect of intensive therapy of diabetes on the development and progression of long term complications in insulin dependent diabetes mellitus.
N Engl J Med, 329 (1993), pp. 977-986
[9.]
EDIC Research Group.
Retinopathy and nefropathy in patients with type 1 diabetes four years after a trial of intensive therapy.
N Engl J Med, 342 (2000), pp. 381-389
[10.]
B. Zinman, H. Tildesley, J.L. Chiasson, E. Tsui, T.H. Strack.
Insulin lispro in CSII. Results of a double blind cross-over study.
Diabetes, 46 (1997), pp. 440-443
[11.]
V. Melki, E. Renard, V. Lassman, S. Boivin, B. Cuerci, H. Hanaire, et al.
Improvement of HbA1c and blood glucose stability in IDDM patients treated with lispro insulin analog in external pumps.
Diabetes Care, 21 (1998), pp. 977-982
[12.]
I. Goicolea, Y. García, A.I. Mancha, E. Ugate, J.A. Vázquez.
Bomba de infusión y complicaciones agudas y crónicas en la diabetes mellitus dependiente de insulina: efectos a los 10 años.
Endocrinología, 43 (1996), pp. 48-52
[13.]
The Diabetes Control and Complications Trial.
Influence of intensive diabetes treatment on quality of life outcomes in the diabetes control and complications trial.
Diabetes Care, 19 (1996), pp. 195-203
[14.]
The Diabetes Control and Complications Trial research group.
Resource utilization and costs of care in the diabetes control and complications trial.
Diabetes Care, 18 (1995), pp. 1468-1478
[15.]
The Diabetes Control and Complications Trial research group.
Lifetime benefits and costs of intensive therapy as practiced in the diabetes control and complications trial.
JAMA, 276 (1996), pp. 1409-1415
[16.]
J. Mesa, A. Pérez, D. Figuerola, M. Fernández Castañer.
Tractament amb bombes d'insulina. Protocols d'actuació en diabetes mellitus.
pp. 21-29
Copyright © 2001. Sociedad Española de Endocrinología y Nutrición